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Simultaneous addition to platelets of submaximal amounts of excitatory agonists acts synergistically in pro- 
voking secretory and aggregatory responses. By measuring changes in intracellular free Ca* + concentration, 
inositol phospholipid metabolism and protein phosphorylation, we verified whether synergism could be evi- 
denced at the level of signal transduction. Challenging platelets with epinephrine only induced minor chan- 
ges on the measured parameters. However, when added together with serotonin, epinephrine amplified mo- 
bilisation of intracellular Ca2 + , PA formatio n, PIP formation, protein kinase C and myosin light chain ki- 
nase activity as compared to the alterations induced by serotonin alone. It is concluded that synergistic ef- 
fects on simultaneous addition of serotonin and epinephrine might originate at the level of signal transduc- 
tion. 
Platelet; Serotonin; Epinephrine; Inositol phospholipid; Ketanserin; (Human) 
1. INTRODUCTION 
Synergistic interactions between excitatory 
agonists on platelet aggregation and secretion are 
widely reported [l-6]. The physiological impor- 
tance of this phenomenon is apparent since under 
conditions of haemostatic stress, minor amounts 
of platelet agonists (as such ineffective) might by 
synergism lead to aggregate formation. The site at 
which separate agonists act synergistically in the 
pathway leading to aggregation after receptor ac- 
tivation is hitherto unknown. In a recent report [7] 
evidence was presented for the synergistic effect of 
different excitatory agonists in increasing in- 
tracellular free Ca2+ concentration. Synergistic ac- 
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tions at the level of signal transduction might be 
important especially since a causal relationship 
between receptor-induced breakdown of inositol 
phospholipids and the increase in intracellular 
Ca2+ is hypothesized. Indeed, inositol triphos- 
phate, a phosphodiesteratic breakdown product of 
phosphatidylinositol 4,5-bisphosphate induces 
Ca2+ release from platelet intracellular Ca2+ stores 
[8-l 11. Beside the inositol phosphates, 
diacylglycerol is formed. This neutral lipid ac- 
tivates protein kinase C [12,13] and is rapidly 
phosphorylated to PA. PA and lyso-PA also cause 
release of Ca2+ from intracellular stores [14]. 
Most platelet excitatory agonists have phos- 
phodiesteratic breakdown of inositol phos- 
pholipids involved in signal transduction [15]. For 
epinephrine, formation of inositol phosphates was 
demonstrated and the diacylglycerol formed ac- 
tivated protein kinase C but only in the presence of 
fibrinogen [ 16- 181 and as a consequence of activa- 
tion of a chain of events leading to stimulation of 
phospholipase A2 and generation of excitatory 
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prostaglandin endoperoxides and thromboxane A2 
117,181. The adrenergic receptor of the platelet 
closely resembles the cYz-receptor [ 19,201. Negative 
coupling to adenylate cyclase was demonstrated 
[21], and its role in platelet activation was ques- 
tioned 17,221. 
As shown in earlier work, platelet activation by 
serotonin involved the breakdown of inositol 
phospholipids as a signal transduction system 
[23-251. 
We now report that the synergistic effect of 
serotonin and epinephrine found on platelet secre- 
tion and aggregation [2,3,6] might originate at the 
level of signal transduction. 
2. EXPERIMENTAL 
Human venous blood and platelet rich plasma 
(PRP) was obtained as described in [24]. 
For intracellular Ca2+ measurements, PRP was 
incubated with 15 PM Quin-2 acetoxymethyl ester 
at 37°C for 12 min. Platelets were separated from 
plasma and extracellular dye by gel filtration on a 
Sepharose-2B column (2.5 x 18 cm) equilibrated 
with 125 mM NaCl, 2.7 mM KCl, 1 mM MgS04, 
0.5 mM Na2HP04, 25 mM Hepes, 10 mM 
glucose, 0.1 mM EGTA, 0.1% BSA at pH 7.4. 
The platelet concentration was adjusted to 2.2 x 
108/ml and 1.2 pmol CaClz/ml was added. 
Platelets were incubated for 45-60 min at 37°C 
before starting measurements. Fluorescence 
readings were recorded at 37°C using a thermostat- 
ted cuvette in a purpose-modified Technicon 
fluoronephelometer (excitation at 340 nm; emis- 
sion at 490 nm). The measurements were corrected 
for dye leakage using 100 PM Mn2+ and 200pM 
CaDTPA [26]. 
Platelets for labelling experiments were prepared 
by gel filtration as described above and incubated 
for the times indicated with approx. 500&i 
[32P]orthophosphate/ml. Phospholipid extraction, 
phospholipid analysis and phosphoprotein analysis 
were performed exactly as described in [24,25]. 
Platelet aggregation, release of intraplatelet 
ATP and biosynthesis of thromboxane AZ in 
human PRP were assessed as described [6,27]. Ag- 
gregation was assessed turbidometrically and 
quantified by measuring the slope (A % Timin) and 
the maximum (A%T) of the first and the second 
wave of aggregation. The amount of TXB2 in the 
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cell-free plasma was measured by radioim- 
munoassay [27]. For the simultaneous measure- 
ment of aggregation and ATP release, 
luciferin-luciferase (4 mg/ml) was incorporated in 
the PRP sample before the induction of aggrega- 
tion. The total amount of ATP released was 
calculated from the luminescence and is expressed 
as PM ATP/1.4 x lo8 platelets. 
Quin-2 acetoxymethyl ester was obtained from 
Calbiochem (La Jolla, USA). Serotonin was from 
Janssen Chimica (Beerse, Belgium). Epinephrine 
came from Sigma and luciferin-luciferase from 
Chronolog (Havertown, USA). Ketanserin was ob- 
tained from Janssen Pharmaceutics (Beerse, 
Belgium). 
3. RESULTS 
Fig.1 illustrates the synergistic effect of 
epinephrine and serotonin on platelet primary ag- 
gregation, release reaction and secondary release- 
dependent platelet recruitment. Serotonin (5 x 
10m6 M) and epinephrine (1.5 x 10m7 M) at con- 
centrations which induced respectively shape 
change followed by a reversible aggregation and a 
weak primary aggregation response, produced a 
strong biphasic aggregation/release reaction when 
combined; both the first wave of the response and 
the release-dependent secondary wave of aggrega- 
tion were amplified. Although the platelet 
response to a large concentration range of 
epinephrine was amplified by serotonin (not 
shown), the synergism was most apparent using 
low concentrations of epinephrine (fig. 1). 
As shown in [7] for combinations of epinephrine 
with U46619, thrombin, ADP or vasopressin, we 
verified whether the increase in intracellular CaZf 
on addition of serotonin to human platelets was 
amplified by epinephrine. Fig.2 illustrates that 
serotonin when added alone increased the 
fluorescence response. The addition of epinephrine 
(lop5 M) had no effect on the Quin-2 signal, when 
added together with serotonin (10m6 M) the 
response was increased. The serotonin-S2 receptor 
antagonist, ketanserin (3 x lOA8 M), completely in- 
hibited the synergistic effect of both agonists on 
Ca2+ mobilisation (fig.2). 
In earlier reports we found that on addition of 
serotonin to human platelets prelabelled with 
[32P]orthophosphate for 70 min, there was a rapid 
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Fig.1. Representative tracings obtained on the same 
human PRP at paired time intervals. Shape change 
followed by reversible aggregation induced by serotonin 
(5HT, 5 x 10m6 M); weak, primary aggregation induced 
by epinephrine (EPI, 1.5 x lo-’ M). Amplification of 
the first wave and induction of release-associated 
irreversible aggregation by combined 5-HT + 
epinephrine. First wave of aggregation: 5-HT, 14.8 * 
2.5%T/min; EPI, 1.5 +0.4%T/min; 5-HT + EPI, 29.8 
f 2.5%7’/min. ATP release (at 3 min): 5-HT, 0 f 0; 
EPI, 0 + 0; 5-HT + EPI, 1.57 f 0.9 x 10m6 M (mean * 
SE, n = 4; p < 0.05 vs single agonists). Plasma TXBZ (at 
3-5 min in pg/lOO&: 5-HT, 59.6 + 7.2; EPI, 47.7 f 
3.4; 5-HT + EPI, 4400 f 605 (mean f SE, n = 4; p < 
0.05 vs single agonists). 
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Fig.2. Platelets loaded with Quin-2 were stimulated with 
either (A) serotonin (5-HT), (B) epinephrine (EPI), (C) 
a mixture of 5-HT and EPI or (D) a mixture of 5-HT and 
EPI after preincubation for 2 min with ketanserin 
Fig.3. Platelets prelabelled with [32P]orthophosphate for 
70 min were stimulated with either serotonin (5-HT), 
epinephrine (EPI), a mixture of 5-HT and EPI or a 
mixture of 5-HT and EPI after preincubation for 10 min 
with ketanserin. At the times indicated duplicate samples 
were taken. Results are representative for 5 separate 
(KTZ). experiments. 
increase in [32P]PA reflecting formation of 
diacylglycerol [23,24]. Fig.3 and table 1 illustrate 
that in similar experimental conditions, 
epinephrine only slightly increased [32P]PA forma- 
tion compared to the increase when platelets were 
challenged with serotonin alone. When added 
simultaneously [32P]PA formation was amplified. 
The stimulatory effect of both agonists was com- 
pletely abolished by ketanserin. The amplificatory 
effect of epinephrine on Ca2+ mobilisation and PA 
formation was maximal at 3 x 1O-6 M (not 
shown). 
Serotonin also induces an increase in protein 
kinase C and myosin light chain kinase activity 
that in 32P-labelled platelets are reflected by an in- 
creased phosphorylation of the 47 kDa and 
20 kDa proteins [23]. Stimulation of platelets with 
serotonin further increases their PIP and decreases 
their PIP2 content as reflected by changes in “P 
labelling [25]. Table 1 illustrates that protein 
phosphorylation and [32P]PIP formation were 
amplified while [32P]PIP~ no longer decreased but 
increased. Epinephrine had a small but significant 
effect on PA formation and protein phosphoryla- 
tion. The 32P content of phosphatidylinositol (PI) 
and phosphatidylcholine was not affected by 
serotonin [25], epinephrine or simultaneous addi- 
tion of both agonists (not shown). 
Prelabelling platelets with [32P]orthophosphate 
for only 5 min, enables quantification of 
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Volume 219, number 2 FEBS LETTERS 
Table 1 
The amplificatory effect of serotonin and epinephrine on inositol phospholipid 
metabolism, protein phosphorylation and Ca’+ mobilisation 
32P incorporation (070 of control) 
Epi 
(3 x 10m6 M) 
5-HT 
(1O-6 M) 
Epi 
(3 x 1O-6 M) + 
5-HT (10m6 M) 
PA 
PIP 
116 k 4 
102 & 1 
(n.s.) 
223 -t 22 p < 0.005 324 * 36 
111 + 3 p < 0.02 1202 5 
PIPZ 101 & 1 93* 1 p < 0.005 107-t 2 
(n.s.) 
40 kDa proteins 
20 kDa proteins 
111 f 4 
119 2 8 
165 + 20 p < 0.01 295 t 46 
156 + 11 p < 0.005 219 & 18 
Ca2+ no increase 197 + 28 p < 0.01 303 ? 52 
(Increase in intracellular Ca’+, nM) 
For “P-incorporation studies, platelets were prelabelled for 70 min. Platelets were 
challenged either with epinephrine (Epi), serotonin (5-HT), a mix of Epi and 5-HT 
or solvent (9’JIo NaCl). After SO s stimulation a single sample was taken for protein 
analysis; after 55 s duplicate samples were taken for lipid analysis. For data 
calculation, the duplicate values from lipid analysis were averaged. The 32P 
incorporation on addition of 9% NaCl was set at 100% (control) for each 
experiment and the corresponding values after addition of agonists were calculated. 
Values represent mean k SE of 4 experiments. Intracellular Ca2+ concentrations 
were obtained as described in section 2. Agonist-induced increase was measured 
20 s after its addition. The intracellular free Ca*+ concentration in the unstimulated 
platelets was 97 f 7 nM. Results represent means +- SE (n = 6) of agonist-induced 
increase in intracellular free Ca”. Except for those indicated by n.s., all the values 
differed significantly (p < 0.05 in paired Student’s r-test) from controls. The 
indicated p values were calculated by pairing the data obtained after addition of 
5-HT and Epi + 5-HT 
July 1987 
serotonin-induced PI turnover [25]. Fig.4 il- 
lustrates that besides the amplificatory effect on 
PA formation, the simultaneous addition of 
epinephrine increased the serotonin-induced syn- 
thesis process of PI. 
4. DISCUSSION 
As reported earlier [2,3,6], serotonin and 
epinephrine act synergistically on platelet aggrega- 
tion and release reaction. The use of Quin-2 as a 
probe for measuring the intracellular free Ca2+ 
concentration did not allow us to measure in- 
creases in Ca2+ on stimulation of isolated human 
platelets with epinephrine. These findings are in 
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accordance with others [7,28-301. In view of 
reported epinephrine-induced changes in Ca2+ us- 
ing other probes [29,30], a local small increase in 
intracellular Ca2+ might occur. The amplificatory 
effect of epinephrine on serotonin-induced Ca2+ 
mobilisation was however detectable by Quin-2 
fluorescence as is the case for all excitatory platelet 
agonists that involve inositol phospholipid 
breakdown and Ca2’ mobilisation in their signal 
transducing system. 
On stimulation of 32P-labelled platelets with 
epinephrine, increases in [32P]PA formation and 
47 kDa protein phosphorylation as measures for 
phospholipase C and protein kinase C activity were 
very low (figs 3,4 and table 1) as compared to those 
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Fig.4. Platelets were preincubated with [32P]ortho- 
phosphate for 5 min. Serotonin (5-HT), epinephrine 
(EPI), a mixture of EPI and 5-HT or the solvent (9% 
NaCl, control) were added (at 0 time on scale). At the 
times indicated duplicate samples were taken. Results 
are representative for 3 separate experiments. 
found on addition of other strong platelet agonists 
[ 12,3 l-331. An amplificatory effect of epinephrine 
on serotonin-induced PA and PIP formation as on 
47 kDa and 20 kDa protein phosphorylation was 
evident (figs 3,4 and table 1). Remarkably, the 
serotonin-induced PIPi breakdown was not 
amplified by epinephrine (table 1): simultaneous 
addition of both agonists increased PIP2 forma- 
tion. In view of the increased PIP formation when 
agonists are added together compared to serotonin 
alone, it is tempting to speculate that the 
amplificatory effect ascribes to an increase in in- 
ositol phospholipid kinase activity thereby 
elevating the substrate availability for 
phospholipase C. 
As an alternative the involvement of guanine 
nucleotide-binding proteins should be hypothe- 
sized since Ni, the inhibitory guanine nucleotide- 
binding protein for adenylate cyclase, has been 
shown to be involved in inositol phospholipid 
breakdown [34-361. Since epinephrine itself is not 
able to decrease CAMP [21] and inhibition of 
adenylate cyclase per se cannot substitute for 
epinephrine in the synergistic effect of combined 
agonists on intracellular Ca2+ increase [7], a 
modulatory effect at the level of CAMP on 
amplification is rather unlikely. 
In conclusion we found that the excitatory 
platelet signal transduction induced by activation 
of the serotonin-S2 receptor is amplified by 
epinephrine. Epinephrine itself had minor effects 
on this signal transducing system. The serotonin-Sz 
receptor antagonist ketanserin abolished the 
synergistic response of serotonin and epinephrine. 
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